Artificial Intelligence for Improved Breast Cancer Screening Accuracy: External Validation, Refinement, and Clinical Translation

人工智能提高乳腺癌筛查准确性：外部验证、细化和临床转化

• 批准号: 10544496
• 负责人: CHRISTOPH I LEE
• 金额: $ 51.77万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10544496
• 关键词: 3-Dimensional; Address; Algorithms; Artificial Intelligence; Benign; Big Data; Biometry; Biopsy; Breast; Breast Cancer Detection; California; Characteristics; Clinical; Code; Collaborations; Community Practice; Computer software; Computers; DNA Sequence Alteration; Data; Data Science; Data Set; Data Storage and Retrieval; Databases; Diagnosis; Diagnostic; Digital Breast Tomosynthesis; Digital Mammography; Equilibrium; Goals; Grant; Health; Human; Image; Imaging Device; Imaging technology; Institution; International; Lead; Link; Machine Learning; Malignant Neoplasms; Mammographic screening; Mammography; Medicine; Metadata; Methods; Modality; Modeling; Molecular; Nature; Oncology; Outcome; Output; Participant; Pathology; Performance; Population; Positioning Attribute; Publications; Radiology Specialty; Randomized, Controlled Trials; Registries; Reverse engineering; Risk; Seminal; Series; Supervision; Techniques; Technology Assessment; Testing; Time; Training; Translating; Universities; Validation; Washington; Woman; algorithm development; algorithmic methodologies; artificial intelligence algorithm; augmented intelligence; breast imaging; clinical implementation; clinical risk; clinical translation; clinically relevant; clinically significant; cloud based; computer aided detection; crowdsourcing; deep learning; digital; experience; genetic risk factor; improved; industry partner; innovation; long short term memory; malignant breast neoplasm; molecular subtypes; mortality; multidisciplinary; novel; novel strategies; patient population; population based; prospective; radiologist; routine screening; screening; tool; tumor

PROJECT SUMMARY Screening mammography saves lives but human interpretation alone is imperfect and is associated with significant harms including ~30,000 missed breast cancers and ~3.8 million false-positives exams each year in the U.S. alone. Traditional computer-aided detection failed to improve screening accuracy, in part due to the static nature of software trained and tested on small datasets decades ago. Recent advances in improved computer processing power, cloud-based data storage capabilities, and availability of large imaging datasets have led to renewed excitement for applying artificial intelligence (AI) to mammography interpretation. We propose a unique academic-industry partnership to validate, refine, scale, and clinically translate our proven 2D mammography AI algorithm to 3D mammography interpretation. Our team helped organize and lead the Dialogue for Reverse Engineering Assessments and Methods (DREAM) Digital Mammography Challenge, an open crowdsourced AI algorithmic challenge that provided >640,000 digital 2D mammogram images and associated clinical metadata to >1,200 coding teams worldwide. Our industry partner for this grant, DeepHealth, Inc., was the top performing team in the DREAM Challenge. With >50% of U.S. facilities now offering 3D mammography for screening, the 50-to-100-fold increase in imaging data represents a new critical barrier for both radiologists and AI algorithm developers. To date, there have been few publications addressing AI-enhanced interpretation of 3D mammography, the emerging screening exam of choice. We will validate our post-DREAM algorithm for 2D mammography (which currently rivals human interpretation alone) using UCLA's Athena Breast Health Network, one of the largest population-based breast imaging registries. We will enhance our 2D AI algorithm with expert radiologist supervision and examine the impact of adding novel non-imaging data parameters, including genetic mutation and tumor molecular subtype data, to help train the AI model to identify more clinically significant cancers. We will use several novel technical algorithmic approaches to scale from 2D to 3D mammography which, in our preliminary studies, have shown improved accuracy beyond radiologist interpretation alone. Finally, we will perform a series of interpretive studies to identify the optimal interface between “black box” outputs and radiologist interpreters, which remains an understudied topic. With >40 million U.S. women undergoing screening each year, seemingly small improvements in overall accuracy would still imply significantly improved population-based outcomes. In summary, we have assembled an unparalleled multidisciplinary team with expertise in machine/deep learning, breast cancer screening accuracy, medicine, oncology, radiology, imaging technology assessment, and biostatistics. We have a proven track record of strong collaboration and are well positioned to validate, enhance, scale, and translate our proven 2D AI algorithm for improved 3D mammography accuracy. Our new end user tool will help tip the balance of routine screening towards greater benefits than harms.

项目总结